C17orf58 Inhibitors
C17orf58 inhibitor compounds such as LY294002 and Wortmannin act as PI3K inhibitors, thereby reducing AKT phosphorylation, which is a common pathway implicated in multiple cellular processes. This reduction may have a downstream effect on the function or expression of C17orf58. Similarly, inhibitors like SB203580, SP600125, and U0126 target different MAP kinases (p38 MAPK, JNK, and MEK1/2 respectively), which are integral to cellular responses to stress and external stimuli. Altering these pathways may influence how C17orf58 operates within the cell, especially if it is involved in stress response or apoptosis.
Inhibitors such as Rapamycin, Bortezomib, and MG132 operate by disrupting broader cellular mechanisms, such as mTOR signaling and proteasome-mediated protein degradation, respectively. These compounds can indirectly affect the turnover and function of numerous proteins, including possibly C17orf58. Moreover, Cyclosporin A affects calcineurin/NFAT signaling, 2-Deoxy-D-glucose interferes with glycolysis, and Thapsigargin and Tunicamycin induce endoplasmic reticulum (ER) stress.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, a kinase that could be upstream of C17orf58, leading to reduced AKT phosphorylation and downstream signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, affecting AKT pathway that can interact with pathways involving C17orf58. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, potentially altering signaling cascades that may intersect with C17orf58 functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which may modulate transcription factors or other proteins interacting with C17orf58. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which may impact protein synthesis and other cellular processes that C17orf58 could be a part of. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Inhibits proteasome, potentially affecting protein turnover including that of C17orf58 or its interactors. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Inhibits proteasome, similar to Bortezomib, potentially impacting C17orf58 stability or function. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Inhibits calcineurin, potentially affecting NFAT signaling that can be relevant to C17orf58's role. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
Glycolysis inhibitor, can alter energy metabolism influencing pathways C17orf58 may be involved in. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Inhibits SERCA, leading to ER stress which could affect protein processing involving C17orf58. | ||||||